Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals Announces Expected Q1 2026 IPR&D Charge
Summary
Regeneron Pharmaceuticals, Inc. expects to report an acquired in-process research and development (IPR&D) charge of approximately $102 million for the first quarter of 2026, which is expected to negatively impact both GAAP and non-GAAP net income per diluted share by approximately $0.81. The charge primarily relates to premiums on equity securities and development milestone payments from collaboration and licensing agreements. The company does not forecast such charges due to the uncertainty of their occurrence and magnitude.
Profitelligence Alerts
Get alerts for REGN
Be first to know when Regeneron Pharmaceuticals, Inc. files with the SEC.
Filing Categories
Advertisement
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.
Official SEC Documents
Advertisement